Laboratorios Farmaceuticos Rovi (ROVI) Stock Overview
Manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for ROVI from our risk checks.
ROVI Community Fair Values
Create NarrativeSee what 52 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Laboratorios Farmaceuticos Rovi, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €84.90 |
| 52 Week High | €86.70 |
| 52 Week Low | €50.05 |
| Beta | 0.33 |
| 1 Month Change | 8.08% |
| 3 Month Change | 16.30% |
| 1 Year Change | 66.14% |
| 3 Year Change | 110.36% |
| 5 Year Change | 74.51% |
| Change since IPO | 749.00% |
Recent News & Updates
Recent updates
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) Using Too Much Debt?
Feb 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
Nov 09Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Nov 06Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574
Jun 14Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year
May 27
Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins
Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume.Shareholder Returns
| ROVI | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 0.8% | -0.2% | -0.6% |
| 1Y | 66.1% | 44.7% | 31.9% |
Return vs Industry: ROVI exceeded the Spanish Pharmaceuticals industry which returned 44.7% over the past year.
Return vs Market: ROVI exceeded the Spanish Market which returned 31.9% over the past year.
Price Volatility
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in ES Market | 6.4% |
| 10% least volatile stocks in ES Market | 1.0% |
Stable Share Price: ROVI has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: ROVI's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,998 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi.
Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary
| ROVI fundamental statistics | |
|---|---|
| Market cap | €4.37b |
| Earnings (TTM) | €140.44m |
| Revenue (TTM) | €743.48m |
Is ROVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROVI income statement (TTM) | |
|---|---|
| Revenue | €743.48m |
| Cost of Revenue | €271.90m |
| Gross Profit | €471.59m |
| Other Expenses | €331.15m |
| Earnings | €140.44m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 2.75 |
| Gross Margin | 63.43% |
| Net Profit Margin | 18.89% |
| Debt/Equity Ratio | 15.7% |
How did ROVI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/23 18:33 |
| End of Day Share Price | 2026/04/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Laboratorios Farmaceuticos Rovi, S.A. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |